Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EBITDA (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBITDA for 2 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 175.34% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$201103.0 for FY2025, 98.7% up from the prior year.
  • EBITDA for Q4 2025 was $2.4 million at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • The five-year high for EBITDA was $11.1 million in Q1 2025, with the low at -$9.9 million in Q3 2025.